BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26188382)

  • 21. Renal cell carcinoma metastatic to Hurthle cell adenoma of thyroid.
    Qian L; Pucci R; Castro CY; Eltorky MA
    Ann Diagn Pathol; 2004 Oct; 8(5):305-8. PubMed ID: 15494939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?
    Chen H; Nicol TL; Zeiger MA; Dooley WC; Ladenson PW; Cooper DS; Ringel M; Parkerson S; Allo M; Udelsman R
    Ann Surg; 1998 Apr; 227(4):542-6. PubMed ID: 9563543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
    Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
    Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experience in Hurthle cell tumors].
    Francomano F; Napolitano L; Scipione P; Savini F; Bajocchi G; Angelucci D
    G Chir; 1998; 19(11-12):449-52. PubMed ID: 9882947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
    Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
    Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgeon-performed ultrasound predictors of malignancy in patients with Hürthle cell neoplasms of the thyroid.
    Parikh PP; Allan BJ; Lew JI
    J Surg Res; 2013 Sep; 184(1):247-52. PubMed ID: 23535112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors.
    Máximo V; Soares P; Lima J; Cameselle-Teijeiro J; Sobrinho-Simões M
    Am J Pathol; 2002 May; 160(5):1857-65. PubMed ID: 12000737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas.
    Fusco A; Viglietto G; Santoro M
    Br J Cancer; 2005 May; 92(10):1817-8. PubMed ID: 15900303
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hürthle-cell thyroid neoplasms: a clinical enigma].
    Cannizzaro M; Fiorenza G; Garofalo L; De Maria A; Cavallaro N; Pulvirenti A; Veroux PF
    Ann Ital Chir; 1999; 70(4):503-8; discussion 508-9. PubMed ID: 10573612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
    McHenry CR; Sandoval BA
    Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of the BRAF and the GRIM-19 mutations in oncocytic (Hürthle cell) solid cell nests of the thyroid.
    Cameselle-Teijeiro J; Ferreira R; Caramés N; Abdulkader I; Máximo V; Soares P; Sobrinho-Simões M
    Am J Clin Pathol; 2012 Apr; 137(4):612-8. PubMed ID: 22431538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors.
    Judkins AR; Roberts SA; Livolsi VA
    Hum Pathol; 1999 Nov; 30(11):1373-6. PubMed ID: 10571520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
    Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
    Elliott DD; Pitman MB; Bloom L; Faquin WC
    Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher body mass index and larger waist circumference may be predictors of thyroid carcinoma in patients with Hürthle-cell lesion/neoplasm fine-needle aspiration diagnosis.
    Arduc A; Dogan BA; Tuna MM; Tutuncu Y; Isik S; Berker D; Guler S
    Clin Endocrinol (Oxf); 2015 Sep; 83(3):405-11. PubMed ID: 25296952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of proliferative activity of thyroid Hürthle cell tumors using PCNA, Ki-67 and AgNOR methods.
    Augustynowicz A; Dziecioł J; Barwijuk-Machała M; Dadan J; Puchalski Z; Sulkowski S
    Folia Histochem Cytobiol; 2004; 42(3):165-8. PubMed ID: 15493577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.
    Cerutti JM; Oler G; Delcelo R; Gerardt R; Michaluart P; de Souza SJ; Galante PA; Huang P; Riggins GJ
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E151-60. PubMed ID: 20926528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follicular and Hürthle cell carcinoma of the thyroid gland.
    Phitayakorn R; McHenry CR
    Surg Oncol Clin N Am; 2006 Jul; 15(3):603-23, ix-x. PubMed ID: 16882500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hurthle cell tumor.
    Chen HY; Benjamin LB; Chen MF
    Int Surg; 1996; 81(2):168-70. PubMed ID: 8912085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy.
    Heikkilä A; Siironen P; Hagström J; Heiskanen I; Sankila R; Louhimo J; Haglund C; Arola J
    APMIS; 2010 Nov; 118(11):846-54. PubMed ID: 20955457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.